43 results on '"Dawn Q. Chong"'
Search Results
2. Association of family history and survival in patients with colorectal cancer: a pooled analysis of eight epidemiologic studies
- Author
-
Dawn Q. Chong, Barbara L. Banbury, Amanda I. Phipps, Xinwei Hua, Jonathan Kocarnik, Ulrike Peters, Sonja I. Berndt, Wen‐Yi Huang, John D. Potter, Martha L. Slattery, Emily White, Peter T. Campbell, Tabitha Harrison, Polly A. Newcomb, and Andrew T. Chan
- Subjects
Colorectal cancer ,family history ,first‐degree relative ,mortality ,survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract A family history of colorectal cancer (CRC) in first‐degree relatives (FDRs) increases the risk of CRC. However, the influence of family history on survival among CRC patients remains unclear. We conducted a pooled analysis of survival in 5010 incident CRC cases. Cox proportional hazards models were used to estimate the association of family history with overall survival (OS) and CRC‐specific survival (CSS). We also assessed the impact of the number of affected FDRs and age at CRC diagnosis in the affected FDRs on survival. Among CRC cases, 819 (16%) patients reported a family history of CRC. There were 1580 total deaths over a median follow‐up of 4.6 years, of which 1046 (66%) deaths were due to CRC. Having a family history of CRC was not associated with OS [hazard ratio (HR), 1.03; 95% confidence interval (CI), 0.89–1.19] or CSS (HR, 1.13; 95% CI, 0.95–1.36)]. There were no associations between the number of affected relatives or age at CRC diagnosis of the affected relative with survival (all Ptrend > 0.05). However, a family history of CRC did confer worse CSS in patients diagnosed with distal colon cancer (HR, 1.45, 95% CI, 1.03–2.04). A family history of CRC was generally not associated with survival after CRC diagnosis. However, having a family history of CRC was associated with worse CRC prognosis in individuals with distal colon cancer, suggesting a possible genetic predisposition with distinct pathogenic mechanism that may lead to worse survival in this group.
- Published
- 2018
- Full Text
- View/download PDF
3. Supplementary Tables S1-S4 from NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project
- Author
-
Katherine A. McGlynn, Peter T. Campbell, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Lynn Rosenberg, Mark P. Purdue, Julie R. Palmer, Martha S. Linet, I-Min Lee, Jill Koshiol, Lindsay Y. King, Eric J. Jacobs, Lifang Hou, Albert R. Hollenbeck, Barry I. Graubard, Edward Giovannucci, John Michael Gaziano, Charles S. Fuchs, Neal D. Freedman, Dawn Q. Chong, Jie Chen, Julie E. Buring, Laura E. Beane-Freeman, Michael C. Alavanja, Andrew T. Chan, Vikrant V. Sahasrabuddhe, and Jessica L. Petrick
- Abstract
Supplementary Table S1. Cohorts Participating in the Liver Cancer Pooling Project with Information on Aspirin Use. Supplementary Table S2. Assessment of aspirin and ibuprofen use, Liver Cancer Pooling Project. Supplemental Table S3. Adjusted* Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between NSAID Use and Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Incidence by Sex, Cigarette Use, Alcohol Consumption, and Ibuprofen Use, Liver Cancer Pooling Project. Supplemental Table S4. Adjusted* Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between NSAID Use and Confirmed or Suspected Hepatocellular Carcinoma, Liver Cancer Pooling Project.
- Published
- 2023
4. Data from NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project
- Author
-
Katherine A. McGlynn, Peter T. Campbell, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Lynn Rosenberg, Mark P. Purdue, Julie R. Palmer, Martha S. Linet, I-Min Lee, Jill Koshiol, Lindsay Y. King, Eric J. Jacobs, Lifang Hou, Albert R. Hollenbeck, Barry I. Graubard, Edward Giovannucci, John Michael Gaziano, Charles S. Fuchs, Neal D. Freedman, Dawn Q. Chong, Jie Chen, Julie E. Buring, Laura E. Beane-Freeman, Michael C. Alavanja, Andrew T. Chan, Vikrant V. Sahasrabuddhe, and Jessica L. Petrick
- Abstract
Chronic inflammation plays a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), the two most common types of liver cancer. A number of prior experimental studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, may potentially protect against liver cancer. However, no observational study has examined the association between aspirin duration and dose or other over-the-counter non-aspirin NSAIDs, such as ibuprofen, and liver cancer incidence. Furthermore, the association between NSAID use and risk of ICC is unclear. As part of the Liver Cancer Pooling Project, we harmonized data on 1,084,133 individuals (HCC = 679, ICC = 225) from 10 U.S.-based prospective cohort studies. Cox proportional hazards regression models were used to evaluate multivariable-adjusted HRs and 95% confidence intervals (CI). Current aspirin use, versus nonuse, was inversely associated with HCC (HR, 0.68; 95% CI, 0.57–0.81), which persisted when restricted to individuals not using non-aspirin NSAIDs and in a 5- and 10-year lag analysis. The association between aspirin use and HCC risk was stronger for users who reported daily use, longer duration use, and lower dosage. Ibuprofen use was not associated with HCC risk. Aspirin use was associated with a reduced ICC risk in men (HR, 0.64; 95% CI, 0.42–0.98) but not women (HR, 1.34; 95% CI, 0.89–2.01; Pinteraction = 0.01). The observed inverse association between aspirin use and liver cancer in our study, together with previous data, suggests the merit of future intervention studies of aspirin and other agents that affect chronic inflammatory pathways for HCC and possibly ICC. Cancer Prev Res; 8(12); 1156–62. ©2015 AACR.
- Published
- 2023
5. Data from Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma
- Author
-
Xuehong Zhang, Andrew T. Chan, Edward L. Giovannucci, Meir Stampfer, Charles S. Fuchs, Dawn Q. Chong, Yanan Ma, Wanshui Yang, Xing Liu, Xiao Luo, Mi Na Kim, and Tracey G. Simon
- Abstract
Prospective data are limited regarding dynamic adulthood weight changes and hepatocellular carcinoma (HCC) risk. We included 77,238 women (1980–2012) and 48,026 men (1986–2012), who recalled young-adult weight [age 18 years (women); 21 years (men)], and provided biennially updated information regarding weight, body mass index (BMI), and comorbidities. Overall adulthood weight change was defined as the difference in weight (kilograms) between young-adulthood and present. Using Cox proportional hazards models, we calculated multivariable adjusted HRs (aHR) and 95% confidence intervals (CI). Over 3,676,549 person-years, we documented 158 incident HCC cases. Elevated HCC risk was observed with higher BMI in both young-adulthood and later-adulthood [continuous aHRs per each 1 unit = 1.05; 95% CI = 1.02–1.09 (Ptrend = 0.019), and 1.08; 95% CI = 1.06–1.10 (Ptrend = 0.004), respectively]. Moreover, overall adulthood weight gain was also significantly associated with increased HCC risk (aHR per each 1-kg increase = 1.03; 95% CI = 1.01–1.08; Ptrend = 0.010), including after further adjusting for young-adult BMI (Ptrend = 0.010) and later-adult BMI (Ptrend = 0.008). Compared with adults with stable weight (±5 kg), the multivariable-aHRs with weight gain of 5–Prevention Relevance:Our data suggest that maintaining a stable weight during adulthood, specifically by preventing weight gain, could represent an important public health strategy for the prevention of hepatocellular carcinoma.
- Published
- 2023
6. Supplementary Data from Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma
- Author
-
Xuehong Zhang, Andrew T. Chan, Edward L. Giovannucci, Meir Stampfer, Charles S. Fuchs, Dawn Q. Chong, Yanan Ma, Wanshui Yang, Xing Liu, Xiao Luo, Mi Na Kim, and Tracey G. Simon
- Abstract
Supplementary Methods Supplementary Tables Table S1. Age-standardized Characteristics of Participants from NHS (n=56,224) and HPFS (n=35,975) With Available Waist Circumference Data in 1986 (NHS) and 1987 (HPFS), According to Adulthood Weight Change Table S2. Waist Circumference and Risk of Incident HCC in the NHS and HPFS Cohorts Table S3. Jointly Classified Analyses of Waist Circumference and BMI and Incident HCC Risk in the Combined NHS and HPFS Cohorts Table S4. Multivariate Risk of Incident HCC According to Weight Change Between Early Adulthood and Mid-life Table S5. Multivariate Risk of Incident HCC According to Weight Change Between Mid-Life and Present Table S6. Multivariate Risk of Incident HCC using an Alternate Definition of Weight Change During Adulthood Table S7. Lagged Analyses of Incident HCC Risk According to Weight Change During Overall Adulthood Table S8. Multivariate Risk of Incident HCC According to Adulthood Weight Change After Excluding Persons with Established Cirrhosis at Baseline Table S9. Multivariate Risk of Incident HCC According to Overall Adulthood Weight Change After Further Accounting for Incident Viral Hepatitis or Cirrhosis Supplementary References
- Published
- 2023
7. Data from Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project
- Author
-
Katherine A. McGlynn, Peter T. Campbell, Jean Wactawski-Wende, Anne Zeleniuch-Jacquotte, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Julie R. Palmer, Martha S. Linet, I-Min Lee, Jill Koshiol, Lindsay Y. King, Albert R. Hollenbeck, Edward L. Giovannucci, John Michael Gaziano, Susan M. Gapstur, Charles S. Fuchs, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Deborah A. Boggs, Laura E. Beane-Freeman, Michael C. Alavanja, Gabriel Y. Lai, Vikrant V. Sahasrabuddhe, Barry I. Graubard, Neal D. Freedman, and Jessica L. Petrick
- Abstract
Background: Coffee consumption has been reported to be inversely associated with hepatocellular carcinoma (HCC), the most common type of liver cancer. Caffeine has chemopreventive properties, but whether caffeine is responsible for the coffee–HCC association is not well studied. In addition, few studies have examined the relationship by sex, and no studies have examined whether there is an association between coffee and intrahepatic cholangiocarcinoma (ICC), the second most common type of liver cancer.Methods: In the Liver Cancer Pooling Project, a consortium of U.S.-based cohort studies, data from 1,212,893 individuals (HCC, n = 860; ICC, n = 260) in nine cohorts were pooled. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) were estimated using proportional hazards regression.Results: Higher coffee consumption was associated with lower risk of HCC (HR>3 cups/day vs. non-drinker, 0.73; 95% CI, 0.53–0.99; Ptrend cups/day = Pinteraction = 0.07). Women who consumed more than three cups of coffee per day were at a 54% lower risk of HCC (HR, 0.46; 95% CI, 0.26–0.81), whereas men had more modest reduced risk of HCC (HR, 0.93; 95% CI, 0.63–1.37). The associations were stronger for caffeinated coffee (HR>3 cups/day vs. non-drinker, 0.71; 95% CI, 0.50–1.01) than decaffeinated coffee (HR, 0.92; 95% CI, 0.55–1.54). There was no association between coffee consumption and ICC.Conclusions: These findings suggest that, in a U.S. population, coffee consumption is associated with reduced risk of HCC.Impact: Further research into specific coffee compounds and mechanisms that may account for these associations is needed. Cancer Epidemiol Biomarkers Prev; 24(9); 1398–406. ©2015 AACR.
- Published
- 2023
8. Figure legends to Figs 1 2 and 3 from Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
- Author
-
Katherine A. McGlynn, Andrew G. Renehan, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Victoria L. Stevens, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Vikrant V. Sahasrabuddhe, Lynn Rosenberg, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Jessica L. Petrick, Julie R. Palmer, Martha S. Linet, I.-Min Lee, Lindsey King, Albert R. Hollenbeck, Barry I. Graubard, Edward L. Giovannucci, J. Michael Gaziano, Mia M. Gaudet, Mridul Datta, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Laura E. Beane Freeman, Michael C. Alavanja, Jill Koshiol, Neal D. Freedman, Christina C. Newton, and Peter T. Campbell
- Abstract
figure legends for supp. figures 1, 2, and 3
- Published
- 2023
9. Supplementary Tables for BMI, WC and diabetes with risk of liver cancer from Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
- Author
-
Katherine A. McGlynn, Andrew G. Renehan, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Victoria L. Stevens, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Vikrant V. Sahasrabuddhe, Lynn Rosenberg, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Jessica L. Petrick, Julie R. Palmer, Martha S. Linet, I.-Min Lee, Lindsey King, Albert R. Hollenbeck, Barry I. Graubard, Edward L. Giovannucci, J. Michael Gaziano, Mia M. Gaudet, Mridul Datta, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Laura E. Beane Freeman, Michael C. Alavanja, Jill Koshiol, Neal D. Freedman, Christina C. Newton, and Peter T. Campbell
- Abstract
Descriptive table or cohorts and results from sensitivity analyses
- Published
- 2023
10. Supplementary Figure 2. Individual participant meta-analysis of waist circumference (per 5 cm) and liver cancer risk in the Liver Cancer Pooling Project from Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
- Author
-
Katherine A. McGlynn, Andrew G. Renehan, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Victoria L. Stevens, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Vikrant V. Sahasrabuddhe, Lynn Rosenberg, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Jessica L. Petrick, Julie R. Palmer, Martha S. Linet, I.-Min Lee, Lindsey King, Albert R. Hollenbeck, Barry I. Graubard, Edward L. Giovannucci, J. Michael Gaziano, Mia M. Gaudet, Mridul Datta, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Laura E. Beane Freeman, Michael C. Alavanja, Jill Koshiol, Neal D. Freedman, Christina C. Newton, and Peter T. Campbell
- Abstract
Results from individual participant meta-analysis of WC. Footnote to Supplementary Figure 2. Multivariable models include age, sex, study, alcohol, smoking, race and body mass index.
- Published
- 2023
11. Supplementary Tables S1-S10, Supplementary Figure S1 from Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project
- Author
-
Katherine A. McGlynn, Peter T. Campbell, Jean Wactawski-Wende, Anne Zeleniuch-Jacquotte, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Julie R. Palmer, Martha S. Linet, I-Min Lee, Jill Koshiol, Lindsay Y. King, Albert R. Hollenbeck, Edward L. Giovannucci, John Michael Gaziano, Susan M. Gapstur, Charles S. Fuchs, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Deborah A. Boggs, Laura E. Beane-Freeman, Michael C. Alavanja, Gabriel Y. Lai, Vikrant V. Sahasrabuddhe, Barry I. Graubard, Neal D. Freedman, and Jessica L. Petrick
- Abstract
Supplementary Table S1: Cohorts participating in analysis of coffee variables, Liver Cancer Pooling Project. Supplementary Table S2: Assessment of coffee consumption, Liver Cancer Pooling Project. Supplementary Table S3: Characteristics of participants in the Liver Cancer Pooling Project by coffee drinking. Supplementary Table S4: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Intrahepatic Cholangiocarcinoma Incidence by Sex, Smoking Status, Body Mass Index, and Diabetes, Liver Cancer Pooling Project. Supplementary Table S5: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Incidence by Caffeine Content; Sensitivity Analysis Excluding WHI and Jointly Modeling Caffeine Content and Drinking Intensity, Liver Cancer Pooling Project. Supplementary Table S6: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Suspected Hepatocellular Carcinoma Incidence by Caffeine Content, Liver Cancer Pooling Project. Supplementary Table S7: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Incidence by Caffeine Content in the AARP Study, Liver Cancer Pooling Project. Supplementary Table S8: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Incidence by Sex in the AARP Study, Liver Cancer Pooling Project. Supplementary Table S9: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Incidence by Caffeine Content excluding the AARP Study, Liver Cancer Pooling Project. Supplementary Table S10: Adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Associations Between Coffee Consumption and Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Incidence by Sex excluding the AARP Study, Liver Cancer Pooling Project. Supplementary Figure S1: Meta-influence Graph of the Influence of Individuals Studies for Associations between Coffee Consumption versus No Consumption and Hepatocellular Carcinoma, Liver Cancer Pooling Project.
- Published
- 2023
12. Supplementary Figure 3. Individual participant meta-analysis of diabetes (yes versus no) and liver cancer risk in the Liver Cancer Pooling Project from Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
- Author
-
Katherine A. McGlynn, Andrew G. Renehan, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Victoria L. Stevens, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Vikrant V. Sahasrabuddhe, Lynn Rosenberg, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Jessica L. Petrick, Julie R. Palmer, Martha S. Linet, I.-Min Lee, Lindsey King, Albert R. Hollenbeck, Barry I. Graubard, Edward L. Giovannucci, J. Michael Gaziano, Mia M. Gaudet, Mridul Datta, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Laura E. Beane Freeman, Michael C. Alavanja, Jill Koshiol, Neal D. Freedman, Christina C. Newton, and Peter T. Campbell
- Abstract
Results from individual participant meta-analysis of diabetes. Multivariable models include age, sex, study, alcohol, smoking, race and body mass index.
- Published
- 2023
13. Supplementary Figure 1. Individual participant meta-analysis of body mass index (per 5 kg/m2) and liver cancer risk in the Liver Cancer Pooling Project from Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
- Author
-
Katherine A. McGlynn, Andrew G. Renehan, Anne Zeleniuch-Jacquotte, Jean Wactawski-Wende, Victoria L. Stevens, Alice J. Sigurdson, Howard D. Sesso, Catherine Schairer, Vikrant V. Sahasrabuddhe, Lynn Rosenberg, Kim Robien, Mark P. Purdue, Jenny N. Poynter, Jessica L. Petrick, Julie R. Palmer, Martha S. Linet, I.-Min Lee, Lindsey King, Albert R. Hollenbeck, Barry I. Graubard, Edward L. Giovannucci, J. Michael Gaziano, Mia M. Gaudet, Mridul Datta, Dawn Q. Chong, Andrew T. Chan, Julie E. Buring, Laura E. Beane Freeman, Michael C. Alavanja, Jill Koshiol, Neal D. Freedman, Christina C. Newton, and Peter T. Campbell
- Abstract
Results from individual participant meta-analysis of BMI. Multivariable models include age, sex, study, alcohol, smoking, and race.
- Published
- 2023
14. Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma
- Author
-
Dawn Q. Chong, Xing Liu, Xuehong Zhang, Mi Na Kim, Xiao Luo, Charles S. Fuchs, Andrew T. Chan, Edward Giovannucci, Wanshui Yang, Tracey G. Simon, Yanan Ma, and Meir J. Stampfer
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Adolescent ,Nurses ,Prospective data ,Weight Gain ,Article ,Young Adult ,Risk Factors ,Internal medicine ,Humans ,Medicine ,Obesity ,Age of Onset ,Adiposity ,Aged ,business.industry ,Proportional hazards model ,Incidence ,Liver Neoplasms ,Weight change ,Middle Aged ,medicine.disease ,Confidence interval ,Massachusetts ,Hepatocellular carcinoma ,Body-Weight Trajectory ,Female ,medicine.symptom ,business ,Body mass index ,Weight gain ,Follow-Up Studies - Abstract
Prospective data are limited regarding dynamic adulthood weight changes and hepatocellular carcinoma (HCC) risk. We included 77,238 women (1980–2012) and 48,026 men (1986–2012), who recalled young-adult weight [age 18 years (women); 21 years (men)], and provided biennially updated information regarding weight, body mass index (BMI), and comorbidities. Overall adulthood weight change was defined as the difference in weight (kilograms) between young-adulthood and present. Using Cox proportional hazards models, we calculated multivariable adjusted HRs (aHR) and 95% confidence intervals (CI). Over 3,676,549 person-years, we documented 158 incident HCC cases. Elevated HCC risk was observed with higher BMI in both young-adulthood and later-adulthood [continuous aHRs per each 1 unit = 1.05; 95% CI = 1.02–1.09 (Ptrend = 0.019), and 1.08; 95% CI = 1.06–1.10 (Ptrend = 0.004), respectively]. Moreover, overall adulthood weight gain was also significantly associated with increased HCC risk (aHR per each 1-kg increase = 1.03; 95% CI = 1.01–1.08; Ptrend = 0.010), including after further adjusting for young-adult BMI (Ptrend = 0.010) and later-adult BMI (Ptrend = 0.008). Compared with adults with stable weight (±5 kg), the multivariable-aHRs with weight gain of 5– Prevention Relevance: Our data suggest that maintaining a stable weight during adulthood, specifically by preventing weight gain, could represent an important public health strategy for the prevention of hepatocellular carcinoma.
- Published
- 2021
15. Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project
- Author
-
Cari M. Kitahara, Yunxia Lu, Howard D. Sesso, Jenny N. Poynter, Xuehong Zhang, Julie R. Palmer, Edward Giovannucci, Jean Wactawski-Wende, Katherine A. McGlynn, Martha S. Linet, Thomas E. Rohan, Peter T. Campbell, John Michael Gaziano, Andrew T. Chan, Andrea A. Florio, Mark P. Purdue, I-Min Lee, Laura E. Beane Freeman, Christina C. Newton, Susan M. Gapstur, Andrew G Renehan, Patrick T. Bradshaw, Tracey G. Simon, Anne Zeleniuch-Jacquotte, Dawn Q. Chong, Kim Robien, Linda M. Liao, Catherine Schairer, Jonathan N. Hofmann, Neal D. Freedman, Jane Demuth, Stephanie A. Smith-Warner, Jill Koshiol, Julie E. Buring, Rashmi Sinha, Victoria A. Kirsh, Jessica L. Petrick, Lynn Rosenberg, and Barry I. Graubard
- Subjects
Male ,Cancer Research ,Gastroenterology ,Body Mass Index ,Cholangiocarcinoma ,0302 clinical medicine ,intrahepatic cholangiocarcinoma ,Prospective Studies ,Prospective cohort study ,Abdominal obesity ,Cancer ,Adiposity ,Liver Disease ,Liver Neoplasms ,Hazard ratio ,hepatocellular carcinoma ,Middle Aged ,Circumference ,Oncology ,030220 oncology & carcinogenesis ,epidemiology ,Female ,Waist Circumference ,medicine.symptom ,Liver cancer ,Liver Cancer ,Adult ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Waist ,Oncology and Carcinogenesis ,gluteofemoral obesity ,Article ,abdominal obesity ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,Internal medicine ,medicine ,Humans ,Obesity ,Oncology & Carcinogenesis ,Aged ,Waist-Hip Ratio ,business.industry ,Prevention ,Carcinoma ,Hepatocellular ,medicine.disease ,Confidence interval ,Bile Duct Neoplasms ,Digestive Diseases ,business - Abstract
Obesity is known to be associated with primary liver cancer (PLC), but the separate effects of excess abdominal and gluteofemoral size are unclear. Thus, we examined the association between waist and hip circumference with risk of PLC overall and by histologic type-hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The Liver Cancer Pooling Project is a consortium of prospective cohort studies that include data from 1,167,244 individuals (PLC n = 2,208, HCC n = 1,154, ICC n = 335). Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CI) were estimated using proportional hazards regression. Waist circumference, per 5 cm increase, was associated with an 11% increased PLC risk (HR = 1.11, 95%CI: 1.09-1.14), including when adjusted for hip circumference (HR = 1.12, 95%CI: 1.08-1.17) and also when restricted to individuals in a normal body mass index (BMI) range (18.5 to
- Published
- 2019
16. Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank
- Author
-
Jean Wactawski-Wende, Edward Giovannucci, Lynn Rosenberg, Xuehong Zhang, Katherine A. McGlynn, Andrea A. Florio, Catherine Schairer, Neal D. Freedman, Thomas E. Rohan, Andrew T. Chan, Tracey G. Simon, Jessica L. Petrick, Dawn Q. Chong, Linda M. Liao, Jill Koshiol, Mark P. Purdue, Laura E. Beane Freeman, Yu Chen, Christopher Cardwell, Victoria A. Kirsh, Anne Zeleniuch-Jacquotte, Julie R. Palmer, Jonathan N. Hofmann, J. Michael Gaziano, Julie E. Buring, Rashmi Sinha, Kim Robien, Peter T. Campbell, Martha S. Linet, Barry I. Graubard, Yunxia Lu, Howard D. Sesso, Susan M. Gapstur, Úna C. McMenamin, I-Min Lee, Jenny N. Poynter, Cari M. Kitahara, and Jennifer W. Bea
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Oncology and Carcinogenesis ,Cholangiocyte proliferation ,Intrahepatic bile ducts ,Hysterectomy ,Article ,Contraceptives, Oral, Hormonal ,Cholangiocarcinoma ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Estrogen Receptor beta ,Humans ,Oncology & Carcinogenesis ,Intrahepatic Cholangiocarcinoma ,Aged ,Biological Specimen Banks ,Proportional Hazards Models ,business.industry ,Hazard ratio ,Liver Neoplasms ,Estrogen Receptor alpha ,Bile duct cancer ,Middle Aged ,medicine.disease ,Biobank ,Hormones ,United Kingdom ,Gene Expression Regulation, Neoplastic ,Bile Ducts, Intrahepatic ,Risk factors ,030220 oncology & carcinogenesis ,Public Health and Health Services ,030211 gastroenterology & hepatology ,Female ,Bile Ducts ,Menopause ,business ,Liver cancer ,Cohort study - Abstract
Background Intrahepatic cholangiocarcinoma (ICC) arises from cholangiocytes in the intrahepatic bile duct and is the second most common type of liver cancer. Cholangiocytes express both oestrogen receptor-α and -β, and oestrogens positively modulate cholangiocyte proliferation. Studies in women and men have reported higher circulating oestradiol is associated with increased ICC risk, further supporting a hormonal aetiology. However, no observational studies have examined the associations between exogenous hormone use and reproductive factors, as proxies of endogenous hormone levels, and risk of ICC. Methods We harmonised data from 1,107,498 women who enroled in 12 North American-based cohort studies (in the Liver Cancer Pooling Project, LCPP) and the UK Biobank between 1980–1998 and 2006–2010, respectively. Cox proportional hazards regression models were used to generate hazard ratios (HR) and 95% confidence internals (CI). Then, meta-analytic techniques were used to combine the estimates from the LCPP (n = 180 cases) and the UK Biobank (n = 57 cases). Results Hysterectomy was associated with a doubling of ICC risk (HR = 1.98, 95% CI: 1.27–3.09), compared to women aged 50–54 at natural menopause. Long-term oral contraceptive use (9+ years) was associated with a 62% increased ICC risk (HR = 1.62, 95% CI: 1.03–2.55). There was no association between ICC risk and other exogenous hormone use or reproductive factors. Conclusions This study suggests that hysterectomy and long-term oral contraceptive use may be associated with an increased ICC risk.
- Published
- 2020
17. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts
- Author
-
Andrew T. Chan, Edward Giovannucci, Jeffrey A. Meyerhardt, Tracey G. Simon, Meir J. Stampfer, Kathleen E. Corey, Xuehong Zhang, Charles S. Fuchs, Xiao Luo, Mi Na Kim, Raymond T. Chung, Yanan Ma, Dawn Q. Chong, and Wanshui Yang
- Subjects
0301 basic medicine ,Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Waist ,Carcinoma, Hepatocellular ,Nurses ,Comorbidity ,Lower risk ,Metabolic equivalent ,Article ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Obesity ,Prospective Studies ,Prospective cohort study ,Exercise ,Adiposity ,Aged ,Aged, 80 and over ,Hepatology ,business.industry ,Hazard ratio ,Liver Neoplasms ,Absolute risk reduction ,Middle Aged ,medicine.disease ,United States ,030104 developmental biology ,030211 gastroenterology & hepatology ,Female ,Waist Circumference ,business ,Body mass index ,Follow-Up Studies - Abstract
BACKGROUND & AIMS: Obesity in adulthood has been associated with increased risk of liver-related mortality. Whether higher levels of physical activity counteract the excess risk conferred by obesity remains unknown. We simultaneously evaluated the long-term impact of physical activity and adiposity on liver-related mortality, within two nationwide populations. METHODS: We conducted a prospective cohort study of 77,238 women and 48,026 men, with detailed, validated assessments of weekly physical activity (metabolic equivalent task [MET]-hours]), adiposity (body mass index [BMI], waist circumference), and diet, alcohol use and clinical comorbidities, biennially from 1986 through 2012. Using Cox proportional hazards regression models, we calculated multivariable adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for liver-related mortality, including death from hepatocellular carcinoma (HCC) and other cirrhosis complications. RESULTS: Over 1,856,226 person-years, we recorded 295 liver-related deaths (108 HCC; 187 cirrhosis). Risk of liver-related mortality increased monotonically with higher BMI during adulthood (P(trend)3 hours/week could have prevented 25% of liver-related deaths (95%CI=0.12-0.38). CONCLUSIONS: In two prospective, nationwide cohorts, both excess adiposity and reduced PA were significant predictors of liver-related mortality. Achieving higher PA levels counteracted the excess liver-related risks associated with obesity.
- Published
- 2019
18. Association of family history and survival in patients with colorectal cancer: a pooled analysis of eight epidemiologic studies
- Author
-
Tabitha A. Harrison, John D. Potter, Sonja I. Berndt, Barbara L. Banbury, Andrew T. Chan, Emily White, Peter T. Campbell, Polly A. Newcomb, Jonathan M. Kocarnik, Xinwei Hua, Martha L. Slattery, Wen Yi Huang, Dawn Q. Chong, Amanda I. Phipps, and Ulrike Peters
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,survival ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Genetic predisposition ,Humans ,Medicine ,Family ,Genetic Predisposition to Disease ,Radiology, Nuclear Medicine and imaging ,First-degree relatives ,Family history ,Medical History Taking ,neoplasms ,Original Research ,Aged ,Proportional Hazards Models ,family history ,business.industry ,Proportional hazards model ,first‐degree relative ,Hazard ratio ,Cancer ,Middle Aged ,medicine.disease ,mortality ,digestive system diseases ,Confidence interval ,3. Good health ,Epidemiologic Studies ,030104 developmental biology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Female ,Colorectal Neoplasms ,business ,Cancer Prevention - Abstract
A family history of colorectal cancer (CRC) in first‐degree relatives (FDRs) increases the risk of CRC. However, the influence of family history on survival among CRC patients remains unclear. We conducted a pooled analysis of survival in 5010 incident CRC cases. Cox proportional hazards models were used to estimate the association of family history with overall survival (OS) and CRC‐specific survival (CSS). We also assessed the impact of the number of affected FDRs and age at CRC diagnosis in the affected FDRs on survival. Among CRC cases, 819 (16%) patients reported a family history of CRC. There were 1580 total deaths over a median follow‐up of 4.6 years, of which 1046 (66%) deaths were due to CRC. Having a family history of CRC was not associated with OS [hazard ratio (HR), 1.03; 95% confidence interval (CI), 0.89–1.19] or CSS (HR, 1.13; 95% CI, 0.95–1.36)]. There were no associations between the number of affected relatives or age at CRC diagnosis of the affected relative with survival (all P trend > 0.05). However, a family history of CRC did confer worse CSS in patients diagnosed with distal colon cancer (HR, 1.45, 95% CI, 1.03–2.04). A family history of CRC was generally not associated with survival after CRC diagnosis. However, having a family history of CRC was associated with worse CRC prognosis in individuals with distal colon cancer, suggesting a possible genetic predisposition with distinct pathogenic mechanism that may lead to worse survival in this group.
- Published
- 2018
19. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project
- Author
-
Julie E. Buring, Rashmi Sinha, Julie R. Palmer, Kim Robien, Marcia L. Stefanick, Jill Koshiol, Edward Giovannucci, Andrew T. Chan, Mark P. Purdue, Jean Wactawski-Wende, Katherine A. McGlynn, Jenny N. Poynter, Gabriella Andreotti, Dawn Q. Chong, Catherine Schairer, Michele M. Doody, Linda M. Liao, I-Min Lee, Lynn Rosenberg, Laura Beane-Freeman, Howard D. Sesso, Susan M. Gapstur, Martha S. Linet, Meir J. Stampfer, John Michael Gaziano, Jessica L. Petrick, Peter T. Campbell, Anne Zeleniuch-Jacquotte, Xuehong Zhang, Jake E. Thistle, Barry I. Graubard, and Neal D. Freedman
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Alcohol Drinking ,medicine.medical_treatment ,Gastroenterology ,Article ,Cholangiocarcinoma ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Tobacco ,medicine ,Humans ,Prospective cohort study ,Aged ,Aged, 80 and over ,business.industry ,Liver Neoplasms ,Smoking ,Hazard ratio ,Case-control study ,Middle Aged ,medicine.disease ,Confidence interval ,3. Good health ,Bile Ducts, Intrahepatic ,Bile Duct Neoplasms ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Smoking cessation ,Female ,030211 gastroenterology & hepatology ,Liver cancer ,business ,Cohort study - Abstract
Background While tobacco and alcohol are established risk factors for hepatocellular carcinoma (HCC), the most common type of primary liver cancer, it is unknown whether they also increase the risk of intrahepatic cholangiocarcinoma (ICC). Thus, we examined the association between tobacco and alcohol use by primary liver cancer type. Methods The Liver Cancer Pooling Project is a consortium of 14 US-based prospective cohort studies that includes data from 1,518,741 individuals (HCC n = 1423, ICC n = 410). Multivariable-adjusted hazards ratios (HRs) and 95% confidence intervals (CI) were estimated using proportional hazards regression. Results Current smokers at baseline had an increased risk of HCC (hazard ratio (HR) = 1.86, 95% confidence interval (CI): 1.57–2.20) and ICC (HR = 1.47, 95% CI: 1.07–2.02). Among individuals who quit smoking >30 years ago, HCC risk was almost equivalent to never smokers (HR = 1.09, 95% CI: 0.74–1.61). Compared to non-drinkers, heavy alcohol consumption was associated with an 87% increased HCC risk (HR≥7 drinks/day = 1.87, 95% CI: 1.41–2.47) and a 68% increased ICC risk (HR≥5 drinks/day = 1.68, 95% CI: 0.99–2.86). However, light-to-moderate alcohol consumption of 0–0.5–
- Published
- 2018
20. Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
- Author
-
Julie E. Buring, Mark P. Purdue, Christina C. Newton, Jean Wactawski-Wende, Julie R. Palmer, Anne Zeleniuch-Jacquotte, Dawn Q. Chong, Michael C. R. Alavanja, Albert R. Hollenbeck, Lindsey King, Victoria L. Stevens, Mia M. Gaudet, Jill Koshiol, Howard D. Sesso, Lynn Rosenberg, Neal D. Freedman, Mridul Datta, Kim Robien, Barry I. Graubard, Andrew T. Chan, Vikrant V. Sahasrabuddhe, J. Michael Gaziano, Laura E. Beane Freeman, Andrew G Renehan, Jessica L. Petrick, Martha S. Linet, Katherine A. McGlynn, Edward Giovannucci, Catherine Schairer, Alice J. Sigurdson, I-Min Lee, Peter T. Campbell, and Jenny N. Poynter
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Waist ,Article ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Aged ,Proportional Hazards Models ,Hepatitis ,business.industry ,Liver Neoplasms ,nutritional and metabolic diseases ,Cancer ,Middle Aged ,medicine.disease ,Obesity ,Endocrinology ,Diabetes Mellitus, Type 2 ,Oncology ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Waist Circumference ,Liver cancer ,business ,Body mass index - Abstract
Incidence rates for liver cancer have increased 3-fold since the mid-1970s in the United States in parallel with increasing trends for obesity and type II diabetes mellitus. We conducted an analysis of baseline body mass index (BMI), waist circumference (WC), and type II diabetes mellitus with risk of liver cancer. The Liver Cancer Pooling Project maintains harmonized data from 1.57 million adults enrolled in 14 U.S.-based prospective studies. Cox regression estimated HRs and 95% confidence intervals (CI) adjusted for age, sex, study center, alcohol, smoking, race, and BMI (for WC and type II diabetes mellitus). Stratified analyses assessed whether the BMI–liver cancer associations differed by hepatitis sera-positivity in nested analyses for a subset of cases (n = 220) and controls (n = 547). After enrollment, 2,162 incident liver cancer diagnoses were identified. BMI, per 5 kg/m2, was associated with higher risks of liver cancer, more so for men (HR = 1.38; 95% CI, 1.30–1.46) than women (HR = 1.25; 95% CI, 1.17–1.35; Pinteraction = 0.02). WC, per 5 cm, was associated with higher risks of liver cancer, approximately equally by sex (overall, HR = 1.08; 95% CI, 1.04–1.13). Type II diabetes mellitus was associated with higher risk of liver cancer (HR = 2.61; 95% CI, 2.34–2.91). In stratified analyses, there was a null association between BMI and liver cancer risk for participants who were sera-positive for hepatitis. This study suggests that high BMI, high WC, and type II diabetes mellitus are associated with higher risks of liver cancer and that the association may differ by status of viral hepatitis infection. Cancer Res; 76(20); 6076–83. ©2016 AACR.
- Published
- 2016
21. Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women
- Author
-
Julie E. Buring, Rashmi Sinha, Edward Giovannucci, Gary Bradwin, Victoria A. Kirsh, Anne Zeleniuch-Jacquotte, Lynn Rosenberg, Julie R. Palmer, Catherine Schairer, Jessica L. Petrick, Tracey G. Simon, Jonathan N. Hofmann, Chantal Guillemette, Linda M. Liao, Mark P. Purdue, Jill Koshiol, Lawrence S. Engel, Stephen K. Van Den Eeden, Dawn Q. Chong, Katherine A. McGlynn, Neal D. Freedman, Andrew T. Chan, J. Michael Gaziano, Frank Z. Stanczyk, Susan M. Gapster, Laura E. Beane Freeman, Cari M. Kitahara, Peter T. Campbell, Xuehong Zhang, Thomas E. Rohan, I-Min Lee, Jean Wactawski-Wende, Andrea A. Florio, Howard D. Sesso, Martha S. Linet, Barry I. Graubard, Yu Chen, and Patrick Caron
- Subjects
0301 basic medicine ,Carcinoma, Hepatocellular ,medicine.drug_class ,Physiology ,Risk Assessment ,Article ,03 medical and health sciences ,0302 clinical medicine ,Sex hormone-binding globulin ,Sex Factors ,Sex Hormone-Binding Globulin ,medicine ,Humans ,Gonadal Steroid Hormones ,Aged ,Hepatology ,biology ,business.industry ,Liver Neoplasms ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Postmenopause ,030104 developmental biology ,Estrogen ,Hepatocellular carcinoma ,Cohort ,biology.protein ,030211 gastroenterology & hepatology ,Female ,Liver cancer ,business ,Hormone - Abstract
Background In almost all countries, incidence rates of liver cancer are 100-200% higher in males than in females. However, this difference is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% of liver cancer cases. Intrahepatic cholangiocarcinoma (ICC) accounts for 12% of cases and has rates only 30% higher in males. Hormones are hypothesized to underlie observed sex differences. We investigated whether prediagnostic circulating hormone and sex hormone binding globulin (SHBG) levels were associated with liver cancer risk, overall and by histology, by leveraging resources from five prospective cohorts. Methods Seven sex steroid hormones and SHBG were quantitated using gas chromatography-tandem mass spectrometry (GC-MS/MS) and competitive electrochemiluminescence immunoassay, respectively, from baseline serum/plasma samples of 191 post-menopausal female liver cancer cases (HCC n=83, ICC n=56) and 426 controls, matched on sex, cohort, age, race/ethnicity, and blood collection date. Odds ratios (ORs) and 95% confidence intervals (CIs) for associations between a one-unit increase in log2 hormone value (approximate doubling of circulating concentration) and liver cancer were calculated using multivariable-adjusted conditional logistic regression. Results A doubling in the concentration of 4-androstenedione was associated with a 50% decreased liver cancer risk (OR=0.50,95%CI=0.30-0.82), while SHBG was associated with a 31% increased risk (OR=1.31,95%CI=1.05-1.63). Examining histology, a doubling of estradiol was associated with a 40% increased risk of ICC (OR=1.40,95%CI=1.05-1.89), but not HCC (OR=1.12,95%CI=0.81-1.54). Conclusions This study provides the first evidence that higher levels of 4-androstenedione may be associated with lower, and SHBG with higher, liver cancer risk in women. However, this study does not support the hypothesis that higher estrogen levels decrease liver cancer risk. Indeed, estradiol may be associated with an increased ICC risk.
- Published
- 2019
22. A prospective study of dairy product intake and the risk of hepatocellular carcinoma in U.S. men and women
- Author
-
Walter C. Willett, Xuehong Zhang, Edward Giovannucci, Tracey G. Simon, Andrew T. Chan, Dawn Q. Chong, Wanshui Yang, Jeffrey A. Meyerhardt, Jing Sui, and Yanan Ma
- Subjects
Male ,Risk ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Lower risk ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,medicine ,Vitamin D and neurology ,Humans ,Prospective Studies ,Prospective cohort study ,Cancer prevention ,business.industry ,Hazard ratio ,Liver Neoplasms ,Middle Aged ,medicine.disease ,United States ,Oncology ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,Dairy Products ,business ,Cohort study - Abstract
Although increasing dairy product intake has been associated with risk of several cancers, epidemiological studies on hepatocellular carcinoma are sparse and have yielded inconsistent results. We prospectively assessed the associations of dairy products (total, milk, butter, cheese and yogurt) and their major components (calcium, vitamin D, fats and protein) with the risk of hepatocellular carcinoma development among 51,418 men and 93,427 women in the Health Professionals Follow-Up Study and the Nurses' Health Study. Diets were collected at baseline and updated every 4 years using validated food frequency questionnaires. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression model. During up to 32 years of follow-up, a total of 164 hepatocellular carcinoma cases were documented. After adjustment for most known hepatocellular carcinoma risk factors, higher total dairy product intake was associated with an increased risk of hepatocellular carcinoma (highest vs. lowest tertile, HR = 1.85, 95% CI: 1.19-2.88; ptrend = 0.009). For the same comparison, we observed significant positive associations of high-fat dairy (HR = 1.81, 95% CI: 1.19-2.76; ptrend = 0.008) and butter (HR = 1.58, 95% CI: 1.06-2.36; ptrend = 0.04) with hepatocellular carcinoma risk. There was a nonsignificant inverse association between yogurt intake and hepatocellular carcinoma risk (HR = 0.72, 95% CI: 0.49-1.05; ptrend = 0.26). Our data suggest that higher intake of high-fat dairy foods was associated with higher, whereas higher yogurt consumption might be associated with lower risk of developing hepatocellular carcinoma among U.S. men and women.
- Published
- 2019
23. Association of Intake of Whole Grains and Dietary Fiber With Risk of Hepatocellular Carcinoma in US Adults
- Author
-
Edward Giovannucci, Andrew T. Chan, Tracey G. Simon, Wanshui Yang, Yanan Ma, Jeffrey A. Meyerhardt, Stephanie A. Smith-Warner, Yue Liu, Qibin Qi, Dawn Q. Chong, and Xuehong Zhang
- Subjects
Adult ,Dietary Fiber ,Male ,Cancer Research ,Carcinoma, Hepatocellular ,Physiology ,Lower risk ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Insulin resistance ,Risk Factors ,Vegetables ,Hyperinsulinemia ,Medicine ,Humans ,030212 general & internal medicine ,Aged ,Original Investigation ,Aged, 80 and over ,Whole Grains ,Bran ,business.industry ,Hazard ratio ,Liver Neoplasms ,food and beverages ,Middle Aged ,Hepatitis B ,medicine.disease ,United States ,Oncology ,Fruit ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,business ,Follow-Up Studies ,Cohort study - Abstract
Importance Increased intake of whole grain and dietary fiber has been associated with lower risk of insulin resistance, hyperinsulinemia, and inflammation, which are known predisposing factors for hepatocellular carcinoma (HCC). Therefore, we hypothesized that long-term intake of whole grains and dietary fiber may be associated with lower risk of HCC. Objective To assess the associations of whole grain and dietary fiber intake with the risk of HCC. Design, Setting, and Participants Cohort study of the intake of whole grains, their subcomponents (bran and germ), and dietary fiber (cereal, fruit, and vegetable) in 125 455 participants from 2 cohorts from the Nurses’ Health Study and the Health Professionals Follow-up Study. Exposures Intake of whole grains, their subcomponents (bran and germ), and dietary fiber (cereal, fruit, and vegetable) were collected and updated almost every 4 years using validated food frequency questionnaires. Main Outcomes and Measures Multivariable hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards regression model after adjusting for most known HCC risk factors. Results After an average follow-up of 24.2 years, we identified 141 patients with HCC among 125 455 participants (77 241 women and 48 214 men (mean [SD] age, 63.4 [10.7] years). Increased whole grain intake was significantly associated with lower risk of HCC (the highest vs lowest tertile intake: HR, 0.63; 95% CI, 0.41-0.96;P = .04 for trend). A nonsignificant inverse HCC association was observed for total bran (HR, 0.70; 95% CI, 0.46-1.07;P = .11 for trend), but not for germ. Increased intake of cereal fiber (HR, 0.68; 95% CI, 0.45-1.03;P = .07 for trend), but not fruit or vegetable fiber, was associated with a nonsignificant reduced risk of HCC. Conclusions and Relevance Increased intake of whole grains and possibly cereal fiber and bran could be associated with reduced risk of HCC among adults in the United States. Future studies that carefully consider hepatitis B and C virus infections are needed to replicate our findings, to examine these associations in other racial/ethnic or high-risk populations, and to elucidate the underlying mechanisms.
- Published
- 2019
24. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
- Author
-
Jeffrey A. Meyerhardt, Jonas F. Ludvigsson, Edward Giovannucci, Dawn Q. Chong, Tracey G. Simon, Xuehong Zhang, Raymond T. Chung, Yanan Ma, Charles S. Fuchs, Kathleen E. Corey, and Andrew T. Chan
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Nurses ,Article ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Carcinoma ,Humans ,Aged ,Aspirin ,business.industry ,Hazard ratio ,Liver Neoplasms ,Cancer ,Middle Aged ,medicine.disease ,United States ,Pooled analysis ,Oncology ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Female ,Skin cancer ,business ,medicine.drug ,Cohort study ,Follow-Up Studies - Abstract
Importance Prospective data on the risk of hepatocellular carcinoma (HCC) according to dose and duration of aspirin therapy are limited. Objective To examine the potential benefits of aspirin use for primary HCC prevention at a range of doses and durations of use within 2 prospective, nationwide populations. Design, Setting, and Participants Pooled analysis of 2 prospective US cohort studies: the Nurses’ Health Study and the Health Professionals Follow-up Study. Data were accessed from November 1, 2017, through March 7, 2018. A total of 133 371 health care professionals who reported data on aspirin use, frequency, dosage, and duration of use biennially since 1980 in women and 1986 in men were included. Individuals with a cancer diagnosis at baseline (except nonmelanoma skin cancer) were excluded. Main Outcomes and Measures Cox proportional hazards regression models were used to calculate multivariable adjusted hazard ratios (HRs) and 95% CIs for HCC. Results Of the 133 371 participants, 87 507 were women and 45 864 were men; in 1996, the median time of follow-up, the mean (SD) age was 62 (8) years for women and 64 (8) years for men. Over more than 26 years of follow-up encompassing 4 232 188 person-years, 108 incident HCC cases (65 women, 43 men) were documented. Compared with nonregular use, regular aspirin use (≥2 standard-dose [325-mg] tablets per week) was associated with reduced HCC risk (adjusted HR, 0.51; 95% CI, 0.34-0.77). This benefit appeared to be dose related: compared with nonuse, the multivariable-adjusted HR for HCC was 0.87 (95% CI, 0.51-1.48) for up to 1.5 standard-dose tablets per week, 0.51 (95% CI, 0.30-0.86) for more than 1.5 to 5 tablets per week, and 0.49 (95% CI, 0.28-0.96) for more than 5 tablets per week ( P for trend = .006). Significantly lower HCC risk was observed with increasing duration ( P for trend = .03); this decrease was apparent with use of 1.5 or more standard-dose aspirin tablets per week for 5 or more years (adjusted HR, 0.41; 95% CI, 0.21-0.77). In contrast, use of nonaspirin nonsteroidal anti-inflammatory drugs was not significantly associated with HCC risk (adjusted HR, 1.09; 95% CI, 0.78-1.51). Conclusions and Relevance This study suggests that regular, long-term aspirin use is associated with a dose-dependent reduction in HCC risk, which is apparent after 5 or more years of use. Similar associations were not found with nonaspirin NSAIDs. Further research appears to be needed to clarify whether aspirin use represents a feasible strategy for primary prevention against HCC.
- Published
- 2018
25. Relationship of prediagnostic body mass index with survival after colorectal cancer: Stage-specific associations
- Author
-
Robert E. Schoen, Tabitha A. Harrison, Dawn Q. Chong, Howard D. Strickler, Lihong Qi, John D. Potter, Andrew T. Chan, Jonathan M. Kocarnik, Emily White, Polly A. Newcomb, Bette J. Caan, Candyce H. Kroenke, Martha L. Slattery, Lifang Hou, Richard B. Hayes, Thomas E. Rohan, Sonja I. Berndt, Jeffrey A. Meyerhardt, Hongmei Nan, Ulrike Peters, and Amanda I. Phipps
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Proportional hazards model ,Overweight ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Epidemiology ,medicine ,030212 general & internal medicine ,medicine.symptom ,Risk factor ,business ,Prospective cohort study ,Survival rate ,Body mass index - Abstract
Higher body mass index (BMI) is a well-established risk factor for colorectal cancer (CRC), but is inconsistently associated with CRC survival. In 6 prospective studies participating in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), 2,249 non-Hispanic white CRC cases were followed for a median 4.5 years after diagnosis, during which 777 died, 554 from CRC-related causes. Associations between prediagnosis BMI and survival (overall and CRC-specific) were evaluated using Cox regression models adjusted for age at diagnosis, sex, study and smoking status (current/former/never). The association between BMI category and CRC survival varied by cancer stage at diagnosis (I-IV) for both all-cause (p-interaction = 0.03) and CRC-specific mortality (p-interaction = 0.04). Compared to normal BMI (18.5-24.9 kg/m(2) ), overweight (BMI 25.0-29.9) was associated with increased mortality among those with Stage I disease, and decreased mortality among those with Stages II-IV disease. Similarly, obesity (BMI ≥30) was associated with increased mortality among those with Stages I-II disease, and decreased mortality among those with Stages III-IV disease. These results suggest the relationship between BMI and survival after CRC diagnosis differs by stage at diagnosis, and may emphasize the importance of adequate metabolic reserves for colorectal cancer survival in patients with late-stage disease.
- Published
- 2016
26. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
- Author
-
Dawn Q. Chong and Andrew X. Zhu
- Subjects
0301 basic medicine ,IDH ,IDH1 ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Review ,Bioinformatics ,medicine.disease_cause ,Malignancy ,Proto-Oncogene Mas ,Targeted therapy ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,medicine ,ROS1 ,Humans ,genetics ,Molecular Targeted Therapy ,Receptor, Fibroblast Growth Factor, Type 2 ,Exome sequencing ,BAP1 ,business.industry ,Cancer ,Proto-Oncogene Proteins c-met ,medicine.disease ,Isocitrate Dehydrogenase ,ErbB Receptors ,030104 developmental biology ,Receptors, Vascular Endothelial Growth Factor ,Oncology ,Bile Duct Neoplasms ,030220 oncology & carcinogenesis ,FGFR2 ,Mutation ,Cancer research ,KRAS ,Gene Fusion ,business - Abstract
// Dawn Q. Chong 1,2 and Andrew X. Zhu 1 1 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA 2 Division of Medical Oncology, National Cancer Centre Singapore, Singapore Correspondence to: Andrew X. Zhu, email: // Keywords : cholangiocarcinoma, genetics, IDH, FGFR2 Received : December 19, 2015 Accepted : April 10, 2016 Published : April 18, 2016 Abstract Cholangiocarcinoma (CCA) is a relatively rare malignancy that arises from the epithelial cells of the intrahepatic, perihilar and distal biliary tree. Intrahepatic CCA (ICC) represents the second most common primary liver cancer, after hepatocellular cancer. Two-thirds of the patients with ICC present with locally advanced or metastatic disease. Despite standard treatment with gemcitabine and cisplatin, prognosis remains dismal with a median survival of less than one year. Several biological plausibilities can account for its poor clinical outcomes. First, despite the advent of next generation and whole exome sequencing, no oncogenic addiction loops have been validated as clinically actionable targets. Second, the anatomical, pathological and molecular heterogeneity, and rarity of CCA confer an ongoing challenge of instituting adequately powered clinical trials. Last, most of the studies were not biomarker-driven, which may undermine the potential benefit of targeted therapy in distinct subpopulations carrying the unique molecular signature. Recent whole genome sequencing efforts have identified known mutations in genes such as epidermal growth factor receptor ( EGFR ), Kirsten rat sarcoma viral oncogene homolog ( KRAS ), v-raf murine sarcoma viral oncogene homolog ( BRAF ) and tumor protein p53 (TP53 ), novel mutations in isocitrate dehydrogenase ( IDH ), BRCA1-Associated Protein 1 ( BAP1 ) and AT-rich interactive domain-containing protein 1A ( ARID1A ), and novel fusions such as fibroblast growth factor receptor 2 ( FGFR2 ) and ROS proto-oncogene 1 ( ROS1 ). In this review, we will discuss the evolving genetic landscape of CCA, with an in depth focus on novel fusions (e.g. FGFR2 and ROS1 ) and somatic mutations (e.g. IDH1/2 ), which are promising actionable molecular targets.
- Published
- 2016
27. Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies
- Author
-
Edward Giovannucci, Trang VoPham, Tracey G. Simon, Xuehong Zhang, Long H. Nguyen, Jeffrey A. Meyerhardt, Kathleen E. Corey, Andrew T. Chan, Yanan Ma, Dawn Q. Chong, Lindsay Y. King, Charles S. Fuchs, Hamed Khalili, and Raymond T. Chung
- Subjects
Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Type 2 diabetes ,Comorbidity ,Article ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Risk factor ,Prospective cohort study ,Aged ,Metabolic Syndrome ,Hepatology ,business.industry ,Hazard ratio ,Liver Neoplasms ,Middle Aged ,medicine.disease ,United States ,Surgery ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Metabolic syndrome ,business ,Dyslipidemia ,Cohort study ,Follow-Up Studies - Abstract
Background: Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk. Methods: From the Nurses' Health Study (NHS), 120,826 women were enrolled in 1980, and from the Health Professionals Follow-up Study (HPFS), 50,284 men were enrolled in 1986, and followed through 2012. Physician-diagnosed T2D was ascertained at baseline and updated biennially. Cox proportional hazards regression models were used to calculate age- and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for incident HCC. Results: Over 32 years of follow-up (4,488,410 person-years), we documented 112 cases of HCC (69 women, 43 men). T2D was associated with an increased HCC risk (multivariable HR 4.59, 95% CI 2.98-7.07), as was an increasing T2D duration (Ptrend
- Published
- 2018
28. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis
- Author
-
Katherine A. McGlynn, Julie E. Buring, Edward Giovannucci, Rashmi Sinha, Christina C. Newton, Mark P. Purdue, Jessica L. Petrick, Julie R. Palmer, Linda M. Liao, Jill Koshiol, Jake E. Thistle, Dawn Q. Chong, Xuehong Zhang, Howard D. Sesso, Andrew T. Chan, Martha S. Linet, Lynn Rosenberg, Meir J. Stampfer, Laura E. Beane Freeman, Jean Wactawski-Wende, Catherine Schairer, Kim Robien, Barry I. Graubard, Thomas E. Rohan, Anne Zeleniuch-Jacquotte, Neal D. Freedman, Jonathan N. Hofmann, J. Michael Gaziano, Cari M. Kitahara, Alison L. Van Dyke, I-Min Lee, Jenny N. Poynter, Peter T. Campbell, and Susan M. Gapstur
- Subjects
Oncology ,medicine.medical_specialty ,Risk Assessment ,Article ,Body Mass Index ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Diabetes mellitus ,Medicine ,Humans ,Obesity ,Intrahepatic Cholangiocarcinoma ,Proportional Hazards Models ,Hepatology ,business.industry ,Incidence ,Liver Neoplasms ,Gastroenterology ,medicine.disease ,digestive system diseases ,Bile Duct Neoplasms ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,Meta-analysis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,business ,Liver cancer ,Risk assessment ,Body mass index - Abstract
OBJECTIVE: Obesity and diabetes are associated with an increased liver cancer risk. However, most studies have examined all primary liver cancers or hepatocellular carcinoma, with few studies evaluating intrahepatic cholangiocarcinoma (ICC), the second most common type of liver cancer. Thus, we examined the association between obesity and diabetes and ICC risk in a pooled analysis and conducted a systematic review/meta-analysis of the literature. DESIGN: For the pooled analysis, we utilized the Liver Cancer Pooling Project, a consortium of 13 US-based, prospective cohort studies with data from 1,541,143 individuals (ICC cases n=414). In our systematic review, we identified 14 additional studies. We then conducted a meta-analysis, combining the results from LCPP with results from the 5 prospective studies identified through September 2017. RESULTS: In the LCPP, obesity and diabetes were associated with a 62% [Hazard Ratio (HR)=1.62, 95% Confidence Interval (CI): 1.24–2.12] and an 81% (HR=1.81, 95%CI: 1.33–2.46) increased ICC risk, respectively. In the meta-analysis of prospectively ascertained cohorts and nested case-control studies, obesity was associated with a 49% increased ICC risk [Relative Risk (RR)=1.49, 95%CI: 1.32–1.70; n=4 studies; I(2)=0%]. Diabetes was associated with a 53% increased ICC risk (RR=1.53, 95%CI: 1.31–1.78; n=6 studies). While we noted heterogeneity between studies (I(2)=67%) for diabetes, results were consistent in subgroup analyses. Results from hospital-based case-control studies (n=9) were mostly consistent, but these studies are potentially subject to reverse causation. CONCLUSIONS: These findings suggest that obesity and diabetes are associated with increased ICC risk, highlighting similar etiologies of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. However, additional prospective studies are needed to verify these associations.
- Published
- 2017
29. Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies
- Author
-
Dawn Q. Chong, Catalina Bonet, Edward Giovannucci, Katharina Nimptsch, Marc J. Gunter, Andrew T. Chan, Michail Katsoulis, Gianluca Severi, Karin Jirström, Sabina Sieri, Miguel Rodríguez-Barranco, Shuji Ogino, Charles S. Fuchs, Ruth C. Travis, Young-Ae Lee, José María Huerta, Mingyang Song, Mazda Jenab, Salvatore Panico, H. Bas Bueno-de-Mesquita, Miren Dorronsoro, Bethany Van Guelpen, José Ramón Quirós, Heinz Freisling, Kim Overvad, Eric B. Rimm, Chunsen Wu, Olle Melander, Majken K. Jensen, Elisabete Weiderpass, Elio Riboli, Heiner Boeing, Franck Carbonnel, Anne Tjønneland, Kana Wu, Marie-Christine Boutron-Ruault, Tilman Kühn, Myrto Barrdahl, Amanda J. Cross, Petra H.M. Peeters, Anja Olsen, Krasimira Aleksandrova, Robin Myte, Tobias Pischon, Domenico Palli, Konstantinos K. Tsilidis, Jürgen Janke, Nimptsch, Katharina, Song, Mingyang, Aleksandrova, Krasimira, Katsoulis, Michail, Freisling, Heinz, Jenab, Mazda, Gunter, Marc J., Tsilidis, Konstantinos K., Weiderpass, Elisabete, Bueno de mesquita, H. Ba, Chong, Dawn Q., Jensen, Majken K., Wu, Chunsen, Overvad, Kim, Kã¼hn, Tilman, Barrdahl, Myrto, Melander, Olle, Jirstrã¶m, Karin, Peeters, Petra H., Sieri, Sabina, Panico, Salvatore, Cross, Amanda J., Riboli, Elio, Van Guelpen, Bethany, Myte, Robin, Huerta, Josã© Marãa, Rodriguez barranco, Miguel, Quirã³s, Josã© Ramã³n, Dorronsoro, Miren, Tjã¸nneland, Anne, Olsen, Anja, Travis, Ruth, Boutron ruault, Marie christine, Carbonnel, Franck, Severi, Gianluca, Bonet, Catalina, Palli, Domenico, Janke, Jã¼rgen, Lee, Young ae, Boeing, Heiner, Giovannucci, Edward L., Ogino, Shuji, Fuchs, Charles S., Rimm, Eric, Wu, Kana, Chan, Andrew T., and Pischon, Tobias
- Subjects
0301 basic medicine ,Oncology ,Adult ,medicine.medical_specialty ,Genotype ,Epidemiology ,Single-nucleotide polymorphism ,Enzyme-Linked Immunosorbent Assay ,ADIPOQ Gene ,Polymorphism, Single Nucleotide ,Article ,03 medical and health sciences ,Mendelian Randomization ,Internal medicine ,Mendelian randomization ,Journal Article ,ADIPOQ ,Medicine ,Humans ,Genetic Predisposition to Disease ,Prospective Studies ,Prospective cohort study ,Alleles ,Genetic Association Studies ,Aged ,Aged, 80 and over ,Adiponectin ,business.industry ,VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 ,Case-control study ,Genetic Variation ,Mendelian Randomization Analysis ,Middle Aged ,Colorectal cancer ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 ,030104 developmental biology ,Endocrinology ,Case-Control Studies ,business ,Colorectal Neoplasms ,Follow-Up Studies - Abstract
This is a pre-print of an article published in European Journal of Epidemiology. The final authenticated version is available online at: https://doi.org/10.1007/s10654-017-0262-y. Higher levels of circulating adiponectin have been related to lower risk of colorectal cancer in several prospective cohort studies, but it remains unclear whether this association may be causal. We aimed to improve causal inference in a Mendelian Randomization meta-analysis using nested case–control studies of the European Prospective Investigation into Cancer and Nutrition (EPIC, 623 cases, 623 matched controls), the Health Professionals Follow-up Study (HPFS, 231 cases, 230 controls) and the Nurses’ Health Study (NHS, 399 cases, 774 controls) with available data on pre-diagnostic adiponectin concentrations and selected single nucleotide polymorphisms in the ADIPOQ gene. We created an ADIPOQ allele score that explained approximately 3% of the interindividual variation in adiponectin concentrations. The ADIPOQ allele score was not associated with risk of colorectal cancer in logistic regression analyses (pooled OR per score-unit unit 0.97, 95% CI 0.91, 1.04). Genetically determined twofold higher adiponectin was not significantly associated with risk of colorectal cancer using the ADIPOQ allele score as instrumental variable (pooled OR 0.73, 95% CI 0.40, 1.34). In a summary instrumental variable analysis (based on previously published data) with higher statistical power, no association between genetically determined twofold higher adiponectin and risk of colorectal cancer was observed (0.99, 95% CI 0.93, 1.06 in women and 0.94, 95% CI 0.88, 1.01 in men). Thus, our study does not support a causal effect of circulating adiponectin on colorectal cancer risk. Due to the limited genetic determination of adiponectin, larger Mendelian Randomization studies are necessary to clarify whether adiponectin is causally related to lower risk of colorectal cancer.
- Published
- 2017
30. Abstract 2680: Intake of whole grain and dietary fiber and risk of hepatocellular carcinoma among U.S. adults
- Author
-
Tracey G. Simon, Smith-Warner Stephanie, Edward Giovannucci, Wanshui Yang, Jeffrey A. Meyerhardt, Andrew T. Chan, Xuehong Zhang, Yue Liu, Yanan Ma, and Dawn Q. Chong
- Subjects
Cancer Research ,medicine.medical_specialty ,Bran ,business.industry ,Hazard ratio ,food and beverages ,Type 2 diabetes ,Hepatitis B ,medicine.disease ,Lower risk ,Gastroenterology ,Insulin resistance ,Oncology ,Internal medicine ,Hepatocellular carcinoma ,medicine ,business ,Body mass index - Abstract
Background Higher intake of whole grain and dietary fiber has been associated with lower risk of insulin resistance, hyperinsulinemia, and inflammation, which are known predisposing factors for hepatocellular carcinoma (HCC). To our knowledge, no epidemiological study has yet examined the association between whole grain intake and HCC risk. Therefore, we hypothesized that long-term intake of whole grain and dietary fiber may be associated with lower risk of developing HCC. Methods We tested this hypothesis by utilizing data from two large U.S. prospective cohorts, the Nurses’ Health Study and Health Professionals Follow-up Study. Intake of whole grain and its subcomponents (bran and germ), and dietary fiber (cereal, fruit, and vegetable) were collected and updated almost every 4 years using validated food frequency questionnaires. Time-varying Cox proportional hazards regression model was utilized to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of of HCC by tertiles of energy-adjusted whole grain and fiber, after adjusting for sex, race, age, body mass index, alcohol drinking, smoking, physical activity, regular aspirin use, and type 2 diabetes. Results During up to 32 years of follow-up, we identified a total of 141 incident HCC cases. Higher whole grain intake was significantly associated with lower risk of HCC (the highest versus lowest tertile intake, HR=0.63, 95% CI: 0.41-0.96, Ptrend=0.04). A suggestive inverse HCC association was found for total bran (HR=0.70, 95% CI: 0.46-1.07, Ptrend=0.11), but not for germ. After mutual adjustment for bran and germ, the inverse association between total bran and HCC persisted (HR=0.66, 95% CI: 0.41-1.07, Ptrend=0.13). Increasing intake of cereal fiber (HR=0.68, 95% CI: 0.45-1.03, Ptrend=0.07), but not fruit or vegetable fiber, was also suggestively associated with reduced risk of HCC. In sensitivity analyses, the results did not materially change after excluding HCC cases with hepatitis B or C virus infections. In addition, we observed similar inverse associations for whole grain, bran and germ, or dietary fiber with risk of HCC subtypes by history of cirrhosis (i.e., cirrhotic versus non-cirrhotic HCC). Conclusions Intake of whole grains, cereal fiber, and bran could be associated with reduced risk of HCC among U.S. adults. Future studies that carefully consider hepatitis B and C virus infections are needed to replicate our findings, to examine these associations in other racial or high-risk populations, and to elucidate the underlying mechanisms. Citation Format: Wanshui Yang, Yanan Ma, Yue Liu, Smith-Warner Stephanie, Tracey G. Simon, Dawn Chong, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Andrew T. Chan, Xuehong Zhang. Intake of whole grain and dietary fiber and risk of hepatocellular carcinoma among U.S. adults [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2680.
- Published
- 2019
31. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer
- Author
-
Dawn Q, Chong, Mary, Manalo, Marlowe, Imperial, Patrick, Teo, Grace, Yong, Matthew, Ng, Iain Bh, Tan, Su Pin, Choo, and Clarinda, Chua
- Subjects
Adult ,Male ,Recombinant Fusion Proteins ,Leucovorin ,Middle Aged ,Irinotecan ,Receptors, Vascular Endothelial Growth Factor ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Camptothecin ,Female ,Fluorouracil ,Neoplasm Metastasis ,Colorectal Neoplasms ,Aged ,Retrospective Studies - Abstract
To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy.This is a retrospective analysis of 19 mCRC patients who received FOLFIRI and aflibercept (4 mg/kg intravenously) every 2 weeks via a Named Patient Program (supported by Sanofi Aventis) in Singapore. Treatment was administered until disease progression or unacceptable toxicities. Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Efficacy and toxicities were summarized using descriptive statistics. Statistical analysis was performed using STATA 12.0 software.The majority (84%) of the patients were of chinese ethnicity. The median age was 59 years, with 63.2% of the patients having an Eastern Cooperative Oncology Group status of 1. Four patients (21.1%) achieved partial response and 8 patients (42.1%) achieved stable disease. After a median follow-up of 9.6 months [95% confidence interval (CI), 2.2-13.1 months], the median OS was 11.6 months (95% CI, 6.1 to not-estimable), and median PFS was 4.1 months (95% CI, 2.2-5.9). Majority of the toxicities were grade 1-2, and include leucopenia (84.2%), anemia (73.7%), liver enzyme elevation (68.4%) and fatigue (68.4%). The most frequently reported grade 3 toxicities were neutropenia and neutropenic complications (both 15.8%). All adverse events resolved with supportive management.The clinical benefit and safety profile of the combination of FOLFIRI/aflibercept in Asian patients with mCRC are consistent with that of Western population. FOLFIRI/aflibercept may be an appropriate therapeutic option in Asian patients with mCRC previously treated with an oxaliplatin-based regimen.
- Published
- 2016
32. Abstract 5256: A prospective study of inflammatory diet potential and risk of hepatocellular carcinoma (HCC)
- Author
-
Dawn Q. Chong, Xuehong Zhang, Fred K. Tabung, Tracey G. Simon, Hamed Khalili, Jeffrey A. Meyerhardt, Trang VoPham, Charles S. Fuchs, Raymond T. Chung, Stephanie A. Smith-Warner, Andrew T. Chan, Lindsay Y. King, Edward Giovannucci, Kathleen E. Corey, Yanan Ma, and Long H. Nguyen
- Subjects
Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,Hepatocellular carcinoma ,Internal medicine ,medicine ,medicine.disease ,business ,Prospective cohort study ,Gastroenterology - Abstract
Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the second-leading cause of cancer-related death worldwide. In the U.S., the incidence rate of HCC has tripled since 1975. Although preliminary evidence suggesting a biological impact of diet on multiple inflammatory pathways implicated in hepatocarcinogenesis, the most comprehensive review by the WCRF/AICR concluded that the relationship between diet and HCC remains largely unknown. HCC is an inflammation-related cancer but few studies have investigated diet quality based on its inflammatory potential in relation to HCC risk. The empirical dietary inflammatory pattern scores (EDIP) score were calculated from validated food frequency questionnaires. It characterized dietary inflammatory potential based on circulating levels of inflammatory bio-markers. We prospectively followed 49,674 men in the Health Professionals Follow-up Study (1986-2012), and 74,139 women in the Nurses' Health Study (1984-2012). Cox regression analyses were used to calculate hazards ratios (HR) for HCC risk adjusting for body mass index, smoking, history of diabetes, race, physical activity, and regular aspirin use. We documented a total of 89 incident HCC cases (44 in women and 45 in men) over 28 years, encompassing 1,522,972 person-years of follow-up. Compared to the lowest tertile, the highest tertile of the EDIP score was associated with a multivariable HR for HCC of 2.86 (95%CI, 1.20-6.81) among women (P-trend=0.01) and of 0.68 (95%CI, 0.31-1.50) among men (P-trend=0.35). Future study is warranted to confirm this finding and elucidate the potential biological basis. Key words: inflammation, dietary patterns, HCC A. T. C. and X. Z contributed equally to this work. Citation Format: Yanan Ma, Tracey G. Simon, Fred K Tabung, Lindsay Y. King, Dawn Q. Chong, Long Nguyen, Trang VoPham, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Hamed Khalili, Stephanie Smith-Warner, Raymond T. Chung, Edward L. Giovannucci, Andrew T. Chan, Xuehong Zhang. A prospective study of inflammatory diet potential and risk of hepatocellular carcinoma (HCC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5256.
- Published
- 2018
33. Tu1496 - Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-Analysis
- Author
-
Andrew T. Chan, Jean Wactowski-Wende, Laura E. Beane Freeman, Jessica L. Petrick, Mark P. Purdue, Barry I. Graubard, Julie R. Palmer, Howard D. Sesso, I-Min Lee, Jill Koshiol, Katherine A. McGlynn, Michele M. Doody, Martha S. Linet, Jake E. Thistle, Meir J. Stampfer, Lynn Rosenberg, Alison L. Van Dyke, Anne Zeleniuch-Jacquotte, Julie E. Buring, Rashmi Sinha, Christina C. Newton, Jonathan N. Hofmann, Catherine Schairer, Xuehong Zhang, Neal D. Freedman, Linda M. Liao, Peter T. Campbell, Thomas E. Rohan, Susan M. Gapstur, Dawn Q. Chong, Kim Robien, Jenny N. Poynter, J. Michael Gaziano, and Edward Giovannucci
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Pooling ,Gastroenterology ,medicine.disease ,Internal medicine ,Diabetes mellitus ,Meta-analysis ,medicine ,Liver cancer ,business ,Body mass index ,Intrahepatic Cholangiocarcinoma - Published
- 2018
34. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
- Author
-
Jeffrey W. Clark, Aparna Govindan, Vikram Deshpande, Dawn Q. Chong, Lipika Goyal, Andrew X. Zhu, Jill N. Allen, Kenneth K. Tanabe, Valentina Nardi, Jennifer Y. Wo, Theodore S. Hong, Nabeel Bardeesy, Jason E. Faris, Lawrence S. Blaszkowsky, Rahul A. Sheth, A. John Iafrate, Cristina R. Ferrone, Supriya K. Saha, Eunice L. Kwak, Darrell R. Borger, David P. Ryan, Hui Zheng, and Janet E. Murphy
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,IDH1 ,Population ,Gene mutation ,IDH2 ,Metastasis ,Cholangiocarcinoma ,Young Adult ,Internal medicine ,Gastrointestinal Cancer ,medicine ,Humans ,education ,Pathological ,Intrahepatic Cholangiocarcinoma ,Aged ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,Prognosis ,Isocitrate Dehydrogenase ,Isocitrate dehydrogenase ,Bile Duct Neoplasms ,Mutation ,Female ,business - Abstract
Background. Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and clinicopathologic features in patients with advanced ICC. Methods. Patients with histologically confirmed advanced ICC who underwent tumor mutational profiling as a routine part of their care between 2009 and 2014 were evaluated. Clinical and pathological data were collected by retrospective chart review for patients with IDHm versus IDH wild-type (IDHwt) ICC. Pretreatment tumor volume was calculated on computed tomography or magnetic resonance imaging. Results. Of the 104 patients with ICC who were evaluated, 30 (28.8%) had an IDH mutation (25.0% IDH1, 3.8% IDH2). The median overall survival did not differ significantly between IDHm and IDHwt patients (15.0 vs. 20.1 months, respectively; p = .17). The pretreatment serum carbohydrate antigen 19-9 (CA19-9) level in IDHm and IDHwt patients was 34.5 and 118.0 U/mL, respectively (p = .04). Age at diagnosis, sex, histologic grade, and pattern of metastasis did not differ significantly by IDH mutation status. Conclusion. The IDH mutation was not associated with prognosis in patients with advanced ICC. The clinical phenotypes of advanced IDHm and IDHwt ICC were similar, but patients with IDHm ICC had a lower median serum CA19-9 level at presentation. Implications for Practice: Previous studies assessing the prognostic impact of the isocitrate dehydrogenase (IDH) gene mutation in intrahepatic cholangiocarcinoma (ICC) mainly focused on patients with early-stage disease who have undergone resection. These studies offer conflicting results. The target population for clinical trials of IDH inhibitors is patients with unresectable or metastatic disease, and the current study is the first to focus on the prognosis and clinical phenotype of this population and reports on the largest cohort of patients with advanced IDH mutant ICC to date. The finding that the IDH mutation lacks prognostic significance in advanced ICC is preliminary and needs to be confirmed prospectively in a larger study.
- Published
- 2015
35. Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer
- Author
-
Charles S. Fuchs, Edward Giovannucci, Kimmie Ng, Shuji Ogino, Dmitriy Kedrin, Dawn Q. Chong, Kana Wu, Andrew T. Chan, Mingyang Song, Jeffrey A. Meyerhardt, and Raaj S. Mehta
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Enzyme-Linked Immunosorbent Assay ,Disease ,Article ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Prospective Studies ,Prospective cohort study ,Survival analysis ,Proportional Hazards Models ,Adiponectin ,Proportional hazards model ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Survival Analysis ,digestive system diseases ,Quartile ,Female ,business ,Colorectal Neoplasms - Abstract
Circulating adiponectin is inversely related to the risk of colorectal cancer. However, its influence on colorectal cancer survival is unclear. We conducted a prospective study to evaluate the association between prediagnostic plasma levels of adiponectin and mortality in patients with colorectal cancer. We identified 621 incident colorectal cancer cases who provided blood specimens prior to diagnosis within the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS). Cox proportional hazards models were used to calculate HRs and 95% confidence intervals (CI). After a median follow-up of 9 years, there were 269 (43%) total deaths, of which 181 (67%) were due to colorectal cancer. Compared with participants in the lowest quartile of adiponectin, those in the highest quartile had multivariate HRs of 1.89 (95% CI, 1.21–2.97; Ptrend = 0.01) for colorectal cancer–specific mortality and 1.66 (95% CI, 1.15–2.39; Ptrend = 0.009) for overall mortality. The apparent increased risk in colorectal cancer–specific mortality was more pronounced in patients with metastatic disease (HR, 3.02: 95% CI, 1.50–6.08). Among patients with colorectal cancer, prediagnostic plasma adiponectin is associated with an increased risk of colorectal cancer–specific and overall mortality and is more apparent in patients with metastatic disease. Adiponectin may be a marker for cancers which develop through specific pathways that may be associated with worsened prognosis. Further studies are needed to validate these findings. Cancer Prev Res; 8(12); 1138–45. ©2015 AACR.
- Published
- 2015
36. NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project
- Author
-
Charles S. Fuchs, Katherine A. McGlynn, Alice J. Sigurdson, Jessica L. Petrick, Anne Zeleniuch-Jacquotte, Michael C. R. Alavanja, Howard D. Sesso, Mark P. Purdue, Lifang Hou, Eric J. Jacobs, Catherine Schairer, Julie E. Buring, Barry I. Graubard, Lynn Rosenberg, Dawn Q. Chong, Laura Beane-Freeman, Edward Giovannucci, Jill Koshiol, Julie R. Palmer, Martha S. Linet, Andrew T. Chan, John Michael Gaziano, Jean Wactawski-Wende, Jie Chen, I-Min Lee, Peter T. Campbell, Lindsay Y. King, Vikrant V. Sahasrabuddhe, Albert R. Hollenbeck, and Neal D. Freedman
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Gastroenterology ,Article ,Cholangiocarcinoma ,Risk Factors ,Internal medicine ,medicine ,Carcinoma ,Humans ,Prospective cohort study ,Intrahepatic Cholangiocarcinoma ,Aged ,Proportional Hazards Models ,Aspirin ,Proportional hazards model ,business.industry ,Hazard ratio ,Anti-Inflammatory Agents, Non-Steroidal ,Liver Neoplasms ,Middle Aged ,medicine.disease ,digestive system diseases ,Oncology ,Bile Duct Neoplasms ,Hepatocellular carcinoma ,Female ,Liver cancer ,business ,medicine.drug - Abstract
Chronic inflammation plays a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), the two most common types of liver cancer. A number of prior experimental studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, may potentially protect against liver cancer. However, no observational study has examined the association between aspirin duration and dose or other over-the-counter non-aspirin NSAIDs, such as ibuprofen, and liver cancer incidence. Furthermore, the association between NSAID use and risk of ICC is unclear. As part of the Liver Cancer Pooling Project, we harmonized data on 1,084,133 individuals (HCC = 679, ICC = 225) from 10 U.S.-based prospective cohort studies. Cox proportional hazards regression models were used to evaluate multivariable-adjusted HRs and 95% confidence intervals (CI). Current aspirin use, versus nonuse, was inversely associated with HCC (HR, 0.68; 95% CI, 0.57–0.81), which persisted when restricted to individuals not using non-aspirin NSAIDs and in a 5- and 10-year lag analysis. The association between aspirin use and HCC risk was stronger for users who reported daily use, longer duration use, and lower dosage. Ibuprofen use was not associated with HCC risk. Aspirin use was associated with a reduced ICC risk in men (HR, 0.64; 95% CI, 0.42–0.98) but not women (HR, 1.34; 95% CI, 0.89–2.01; Pinteraction = 0.01). The observed inverse association between aspirin use and liver cancer in our study, together with previous data, suggests the merit of future intervention studies of aspirin and other agents that affect chronic inflammatory pathways for HCC and possibly ICC. Cancer Prev Res; 8(12); 1156–62. ©2015 AACR.
- Published
- 2015
37. Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project
- Author
-
Deborah A. Boggs, Michael C. R. Alavanja, Anne Zeleniuch-Jacquotte, Barry I. Graubard, Peter T. Campbell, Lindsay Y. King, Martha S. Linet, Dawn Q. Chong, Katherine A. McGlynn, Catherine Schairer, John Michael Gaziano, Gabriel Y. Lai, Mark P. Purdue, Julie R. Palmer, Edward Giovannucci, Laura Beane-Freeman, Jean Wactawski-Wende, Susan M. Gapstur, Howard D. Sesso, Jill Koshiol, Jessica L. Petrick, Charles S. Fuchs, Alice J. Sigurdson, Andrew T. Chan, I-Min Lee, Kim Robien, Julie E. Buring, Jenny N. Poynter, Albert R. Hollenbeck, Neal D. Freedman, and Vikrant V. Sahasrabuddhe
- Subjects
Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Epidemiology ,Population ,Drinking ,Lower risk ,Gastroenterology ,Coffee ,Article ,Cholangiocarcinoma ,chemistry.chemical_compound ,Sex Factors ,Internal medicine ,Caffeine ,medicine ,Humans ,education ,Intrahepatic Cholangiocarcinoma ,Aged ,education.field_of_study ,business.industry ,Hazard ratio ,Liver Neoplasms ,Middle Aged ,medicine.disease ,United States ,Bile Ducts, Intrahepatic ,Oncology ,chemistry ,Bile Duct Neoplasms ,Hepatocellular carcinoma ,Female ,Liver cancer ,business ,Cohort study - Abstract
Background: Coffee consumption has been reported to be inversely associated with hepatocellular carcinoma (HCC), the most common type of liver cancer. Caffeine has chemopreventive properties, but whether caffeine is responsible for the coffee–HCC association is not well studied. In addition, few studies have examined the relationship by sex, and no studies have examined whether there is an association between coffee and intrahepatic cholangiocarcinoma (ICC), the second most common type of liver cancer. Methods: In the Liver Cancer Pooling Project, a consortium of U.S.-based cohort studies, data from 1,212,893 individuals (HCC, n = 860; ICC, n = 260) in nine cohorts were pooled. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) were estimated using proportional hazards regression. Results: Higher coffee consumption was associated with lower risk of HCC (HR>3 cups/day vs. non-drinker, 0.73; 95% CI, 0.53–0.99; Ptrend cups/day = 3 cups/day vs. non-drinker, 0.71; 95% CI, 0.50–1.01) than decaffeinated coffee (HR, 0.92; 95% CI, 0.55–1.54). There was no association between coffee consumption and ICC. Conclusions: These findings suggest that, in a U.S. population, coffee consumption is associated with reduced risk of HCC. Impact: Further research into specific coffee compounds and mechanisms that may account for these associations is needed. Cancer Epidemiol Biomarkers Prev; 24(9); 1398–406. ©2015 AACR.
- Published
- 2015
38. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality
- Author
-
Zhi Rong Qian, Charles S. Fuchs, Shuji Ogino, Kimmie Ng, Andrew T. Chan, Reiko Nishihara, Edward Giovannucci, Mingyang Song, Dawn Q. Chong, Teppei Morikawa, Kana Wu, Jeffrey A. Meyerhardt, and Raaj S. Mehta
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Growth Differentiation Factor 15 ,Time Factors ,Colorectal cancer ,Enzyme-Linked Immunosorbent Assay ,Risk Assessment ,Article ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Prospective Studies ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,Hepatology ,biology ,Proportional hazards model ,business.industry ,Hazard ratio ,C-reactive protein ,Gastroenterology ,Middle Aged ,medicine.disease ,Prognosis ,Confidence interval ,Up-Regulation ,Quartile ,Cyclooxygenase 2 ,Immunology ,Multivariate Analysis ,biology.protein ,Nurses' Health Study ,Female ,GDF15 ,Inflammation Mediators ,business ,Colorectal Neoplasms - Abstract
Background & Aims Patients with colorectal cancer (CRC) have high circulating levels of macrophage inhibitory cytokine-1 (MIC1 or growth differentiation factor 15), a marker of inflammation that might be involved in carcinogenesis. We analyzed blood samples collected from individuals before they were diagnosed with CRC to determine whether levels of MIC1 were associated with mortality. Methods We collected data on survival of 618 participants diagnosed with CRC who provided prediagnosis blood specimens in 1990 (Nurses' Health Study) and 1994 (Health Professionals' Follow-up Study) and were followed through 2010. Levels of MIC1 were measured by enzyme-linked immunosorbent assay and then were categorized into quartiles based on the known distribution of MIC1 levels among previously matched individuals without CRC (controls) within each cohort. We then examined the association of MIC1 levels with overall and CRC-specific mortality using Cox proportional hazards models, with adjustments for mortality-associated risk factors and other plasma markers of inflammation. We also assessed the relationship between levels of MIC1 and levels of prostaglandin-endoperoxide synthase 2 expression (PTGS2 or cyclooxygenase-2), measured in 245 tumor samples by immunohistochemistry. Results Compared with participants in the lowest quartile for plasma level of MIC1, the multivariate hazard ratio for CRC-specific death for participants in the highest quartile of MIC1 level was 2.40 (95% confidence interval: 1.33−4.34; P for linear trend = .009). The association of MIC1 with survival varied with level of PTGS2 expression in tumor samples ( P interaction = .04). For individuals with PTGS2-positive tumors, the hazard ratio for CRC-specific death among those with high levels of MIC1 (equal to or greater than the median) was 2.13 (95% confidence interval: 0.99−4.58) compared with participants with low levels of MIC1 (below the median). In individuals with PTGS2-negative CRC, a high level of MIC1 was not associated with an increased risk of CRC-specific death (multivariate hazard ratio = 0.61; 95% confidence interval: 0.13−2.93). Conclusions Based on an analysis of blood and colorectal tumor samples from 2 large studies, high plasma levels of MIC1 (growth differentiation factor 15) before diagnosis of CRC are associated with greater CRC-specific mortality, particularly in individuals with PTGS2-positive tumors.
- Published
- 2014
39. Abstract 3007: Tobacco smoking, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project
- Author
-
Dawn Q. Chong, Anne Zeleniuch-Jacquotte, Gabriella Andreotti, Julie E. Buring, Rashmi Sinha, Martha S. Linet, Meir J. Stampfer, Katherine A. McGlynn, Xuehong Zhang, John Michael Gaziano, Marcia L. Stefanick, Barry I. Graubard, Howard D. Sesso, Julie R. Palmer, Neal D. Freedman, Michele M. Doody, Andrew T. Chan, Kim Robien, Linda M. Liao, Lynn Rosenberg, Jake E. Thistle, Catherine Schairer, Jill Koshiol, Jean Wactawski-Wende, Jessica L. Petrick, Laura Beane-Freeman, Edward Giovannucci, Susan M. Gapstur, Mark P. Purdue, Peter T. Campbell, I-Min Lee, and Jenny N. Poynter
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,education.field_of_study ,business.industry ,medicine.medical_treatment ,Population ,Hazard ratio ,Cancer ,medicine.disease ,Internal medicine ,Hepatocellular carcinoma ,Cohort ,medicine ,Smoking cessation ,Liver cancer ,business ,education ,Cohort study - Abstract
Background: Since 1980, liver cancer has been among the most rapidly increasing cancer types in the United States (US), with 5-year survival rates of approximately 17%. While tobacco and alcohol are known to be associated with primary liver cancer, it is unclear whether they only increase the risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, or whether they also increase risk of intrahepatic cholangiocarcinoma (ICC), second most common histologic type. Additionally, it is unclear what amount of alcohol consumption is associated with an increased risk of liver cancer. As liver cancer is a rare cancer type, we conducted a study of pooled data from the National Cancer Institute Cohort Consortium to examine the associations between smoking and alcohol use and liver cancer, stratified by histologic subtype. Methods: In the Liver Cancer Pooling Project, a consortium of US-based cohort studies, we pooled data from 1,518,741 individuals (HCC n=1,423, ICC n=410) in 14 cohorts. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CI) were estimated using proportional hazards regression. Cubic splines were used to model the association between alcohol and liver cancer risk. Results: Compared to never smokers, both former and current smokers at study baseline had an increased risk of ICC (HR=1.32, 95% CI: 1.03-1.68 and HR=1.47, 95% CI: 1.07-2.02, respectively) and HCC (HR=1.24, 95% CI: 1.08-1.43 and HR=1.86, 95% CI: 1.57-2.20, respectively). This finding was consistent for heavier smoking intensity, longer duration of smoking, and more pack-years of smoking. Heavy alcohol consumption was associated with an 87% increased risk of HCC (HR≥7 drinks/day v. non-drinker=1.87, 95% CI: 1.41-2.47) and a non-significant 68% increased risk of ICC (HR≥5 drinks/day v. non-drinker=1.68, 95% CI: 0.99-2.86). Risk of HCC significantly increased at 4.5 alcoholic drinks per day, while risk of ICC was non-significantly increased with any amount of consumption. Conclusions: These findings suggest that, in a US population, cigarette smoking is associated with an increased risk of both histologic subtypes of primary liver cancer - HCC and ICC. In contrast, alcohol consumption was primarily associated with an increased risk of HCC. These results suggest that smoking cessation and alcohol reduction programs could be important intervention opportunities for these lethal cancer types. Citation Format: Jessica Leigh Petrick, Peter T. Campbell, Jill Koshiol, Jake E. Thistle, Gabriella Andreotti, Laura E. Beane-Freeman, Julie E. Buring, Andrew T. Chan, Dawn Q. Chong, Michele M. Doody, Susan M. Gapstur, John Michael Gaziano, Edward Giovannucci, Barry I. Graubard, I-Min Lee, Linda M. Liao, Martha S. Linet, Julie R. Palmer, Jenny N. Poynter, Mark P. Purdue, Kim Robien, Lynn Rosenberg, Catherine Schairer, Howard D. Sesso, Rashmi Sinha, Meir J. Stampfer, Marcia Stefanick, Jean Wactawski-Wende, Xuehong Zhang, Anne Zeleniuch-Jacquotte, Neal D. Freedman, Katherine A. McGlynn. Tobacco smoking, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3007. doi:10.1158/1538-7445.AM2017-3007
- Published
- 2017
40. Chemotherapy and antiangiogenics in biliary tract cancer
- Author
-
Dawn Q. Chong, Lipika Goyal, Dan G. Duda, and Andrew X. Zhu
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Biliary tract cancer ,business.industry ,Internal medicine ,medicine.medical_treatment ,medicine ,MEDLINE ,business - Abstract
Lancet Oncology, The - In Press.Proof corrected by the author Available online since mercredi 15 juillet 2015
- Published
- 2015
- Full Text
- View/download PDF
41. Association of family history and survival in patients with colorectal cancer
- Author
-
Sonja I. Berndt, Jonathan M. Kocarnik, Xinwei Hua, Andrew T. Chan, John D. Potter, Wen-Yi Huang, Martha L. Slattery, Dawn Q. Chong, Peter T. Campbell, Emily White, Amanda I. Phipps, Polly A. Newcomb, Ulrike Peters, Tabitha A. Harrison, and Barbara L. Banbury
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,medicine.disease ,digestive system diseases ,Internal medicine ,medicine ,In patient ,Family history ,business ,neoplasms - Abstract
3594Background: A family history of colorectal cancer (CRC) in first-degree relatives (FDRs) increases the risk of CRC. However, beyond rare hereditary CRC syndromes, the influence of family histor...
- Published
- 2016
42. Sa1932 Prediagnostic Circulating Macrophage Inhibitory Cytokine-1 (MIC-1) Is Associated With Worsened Survival Among Patients With Colorectal Cancer
- Author
-
Andrew T. Chan, Dawn Q. Chong, Charles S. Fuchs, Teppei Morikawa, Shuji Ogino, Mingyang Song, Zhi Rong Qian, Edward Giovannucci, Kimmie Ng, Jeffrey A. Meyerhardt, Raaj S. Mehta, Reiko Nishihara, and Kana Wu
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,Adenoma ,Microarray ,Colorectal cancer ,Gastroenterology ,Methylation ,Biology ,medicine.disease ,CpG site ,Internal medicine ,DNA methylation ,medicine ,Cancer research ,MTT assay ,Gene - Abstract
Background and aim: Aberrant DNA methylation plays critical roles in the development of colorectal cancers (CRCs). Laterally spreading tumors (LSTs) are generally defined as lesions greater than 10 mm in diameter with a low vertical axis that extend laterally along the luminal wall. Those flat lesions are thought to be less invasive because they are likely to be found in the adenoma stage or intramucosal CRCs. On the other hand, a subset of CRCs are known to develop from nonpolypoid lesions and the nonpolypoid submucosal invasive CRCs were smaller than did the polypoid cancers. We aimed to identify DNA methylation changes, which are associated with growth pattern and invasiveness of colorectal tumors. Methods: Methylated CpG island amplification coupled with CpG island microarray (MCAM) analysis was carried out to screen for differentially methylated genes between large (≥20 mm in diameter) noninvasive tumors (NTs) and small (
- Published
- 2015
43. A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers
- Author
-
Wan-Teck Lim, Guek Eng Lee, Noan Minh Chau, Mei-Kim Ang, Eng Huat Tan, Balram Chowbay, Daniel Shao-Weng Tan, Dawn Q. Chong, Thuan Tong Tan, Quan Sing Ng, John E. Connolly, and Liz Zhong
- Subjects
Cancer Research ,Everolimus ,Oncology ,Lytic cycle ,business.industry ,medicine ,Cancer research ,Histone deacetylase ,medicine.disease_cause ,business ,Epstein–Barr virus ,PI3K/AKT/mTOR pathway ,medicine.drug - Abstract
3098 Background: Histone deacetylase and mTOR inhibition circumvent critical EBV-oncogenic pathways with preclinical studies demonstrating lytic induction in EBV infected cells, as well as immunomodulatory and antiangiogenic effects. Methods: Patients (Pt) with advanced solid tumors enriched for EBV–related cancers were enrolled to determine safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity. LBH was instituted 7-days prior to combination treatment. NPC pt received antiviral prophylaxis of either acyclovir (Ac) or valaciclovir (Vc). Serum EBV DNA levels (EBNA-1) were measured weekly and plasma cytokines profiled using a 31-plex Luminex panel. Results: 15 pt have been treated (M:F 13:2, median age 50, R: 38-63) 10 NPC, 5 non-NPC (colon, RCC, breast, gastric, sarcoma) at 3 dose levels – LBH (3x/wk)-EVE (daily):10-2.5, 10-5, 15-5. Two dose limiting toxicities of G4 (grade) thrombocytopenia were observed at LBH15-RAD5. Significant adverse events (AE) (G≥3) were dysphagia (1) and thrombocytopenia (3). Common AEs (G1/2) included fatigue (80%), anorexia (60%), mucositis (53%), xerostomia (26%), dysphagia (26%). Two minor responses were seen (1 NPC, 1 breast) and 2 pt (1 NPC, 1 RCC) had prolonged stable disease (>16 weeks). Modulation of EBV DNA titres was seen only in NPC pt, with median fold-change from baseline of 10.9 (0.05-174). Pt on Ac prophylaxis (n=5) had significant increases in DNA titres (9-174 fold), while those on Vc (n=4) were less pronounced (0.05-11 fold, p
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.